Hospital La Milagrosa S.A.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Hospital La Milagrosa S.A. is conducting studies focused on blood clotting disorders to improve prevention and treatment outcomes.
- Evaluation of novel anticoagulants versus standard therapy in patients with cancer‑associated VTE
- Assessment of recurrence risk and bleeding safety in gastrointestinal and genitourinary cancer settings
- Comparison of new agents with established drugs to reduce clot recurrence
These trials aim to test new therapeutic options that could lower the chance of clot re‑occurrence while maintaining safety.
Immune System Diseases
Research at the site includes investigations into autoimmune inflammatory conditions to refine dosing and improve patient quality of life.
- Pharmacokinetic study of sarilumab in children and adolescents with systemic juvenile idiopathic arthritis
- Determination of optimal dosing regimens for effective disease control
- Safety monitoring across pediatric age groups
The goal is to identify safe and effective treatment strategies for young patients with severe joint inflammation.
Neoplasms
The oncology program at Hospital La Milagrosa evaluates innovative therapies for advanced lung cancers.
- Comparison of a biosimilar checkpoint inhibitor with a reference drug in metastatic non‑small cell lung cancer
- Study of targeted therapy effectiveness in ROS1‑positive NSCLC patients with active brain metastases
- Assessment of overall response rates using standardized imaging criteria
These studies seek to enhance survival and tumor control by testing new agents against established standards.
Nervous System Diseases
Trials at the center focus on neurological disorders, aiming to reduce seizure burden and improve cognitive function.
- Evaluation of novel antiseizure medication PRAX‑628 for focal and generalized tonic‑clonic seizures
- Investigation of LP352 in Dravet syndrome and broader developmental and epileptic encephalopathies
- Long‑term safety study of a new therapy for CDKL5 deficiency disorder
- Assessment of donepezil on cognition in patients with Parkinson’s disease
These projects strive to provide better symptom control and preserve mental abilities for individuals living with chronic brain conditions.
Respiratory Tract Diseases
The site’s pulmonary research targets airway inflammation to lower exacerbations and improve lung health.
- Randomized trial of lunsekimig versus placebo to prevent asthma attacks
- Evaluation of depemokimab in COPD patients with type‑2 inflammatory profiles
- Long‑term safety monitoring of inhaled therapy in moderate‑to‑severe asthma
These studies aim to test new biologic and small‑molecule treatments that could reduce flare‑ups and enhance daily breathing capacity.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 29 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital La Milagrosa S.A.
lock Showing 1 of 32 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy (X-TOLE4) | Xenon Pharmaceuticals Inc. | Phase III | Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 29 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abelacimab | 3 | Unknown | 2022-08-10 | 2023-10-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.